CO2021003290A2 - Método para obtener una población enriquecida de células madre mesenquimales funcionales, células obtenidas de la misma y composiciones que las comprenden. - Google Patents
Método para obtener una población enriquecida de células madre mesenquimales funcionales, células obtenidas de la misma y composiciones que las comprenden.Info
- Publication number
- CO2021003290A2 CO2021003290A2 CONC2021/0003290A CO2021003290A CO2021003290A2 CO 2021003290 A2 CO2021003290 A2 CO 2021003290A2 CO 2021003290 A CO2021003290 A CO 2021003290A CO 2021003290 A2 CO2021003290 A2 CO 2021003290A2
- Authority
- CO
- Colombia
- Prior art keywords
- mesenchymal stem
- stem cells
- enriched population
- compositions
- obtaining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un método para obtener una composición que comprende una población enriquecida de células madre mesenquimales funcionales para el transporte hipotérmico y la administración local de dicha población enriquecida de células madre mesenquimales funcionales en terapia. Por último, también se describe el uso de dicha población enriquecida de células madre mesenquimales funcionales, y de las composiciones que las comprenden, obtenidas mediante el método descrito, en el tratamiento autólogo o alógeno de enfermedades susceptibles a terapia con células madre mesenquimales, mediante tratamientos, o bien locales, o bien sistémicos, y más particularmente en el tratamiento de enfermedades osteoarticulares, tales como, discopatía degenerativa, osteoartritis y reparación ósea; en lupus eritematoso, enfermedad de injerto contra huésped y otras enfermedades autoinmunitarias; en insuficiencia vascular periférica y otras enfermedades cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382679 | 2018-09-20 | ||
| PCT/EP2019/074991 WO2020058324A1 (en) | 2018-09-20 | 2019-09-18 | Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021003290A2 true CO2021003290A2 (es) | 2021-06-10 |
Family
ID=63722321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0003290A CO2021003290A2 (es) | 2018-09-20 | 2021-03-12 | Método para obtener una población enriquecida de células madre mesenquimales funcionales, células obtenidas de la misma y composiciones que las comprenden. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11930808B2 (es) |
| EP (1) | EP3852525B1 (es) |
| JP (1) | JP7401865B2 (es) |
| KR (1) | KR102506822B1 (es) |
| CN (1) | CN112770628B (es) |
| AU (1) | AU2019341538B2 (es) |
| BR (1) | BR112021005257B1 (es) |
| CA (1) | CA3112505C (es) |
| CL (1) | CL2021000656A1 (es) |
| CO (1) | CO2021003290A2 (es) |
| ES (1) | ES2948810T3 (es) |
| IL (1) | IL281105B (es) |
| MX (1) | MX2021002932A (es) |
| PT (1) | PT3852525T (es) |
| WO (1) | WO2020058324A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| WO2021071430A1 (en) * | 2019-10-08 | 2021-04-15 | Cellresearch Corporation Pte. Ltd. | A mesenchymal stem cell storing or transport formulation and methods of making and using the same |
| FR3105911B1 (fr) * | 2020-01-02 | 2022-03-04 | Vetbiobank | Procédé de congélation et de conservation de cellules stromales néonatales |
| WO2022020210A1 (en) | 2020-07-18 | 2022-01-27 | Ossium Health, Inc. | Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion |
| CA3195653A1 (en) | 2020-10-14 | 2022-04-21 | Ossium Health, Inc. | Systems and methods for extraction and cryopreservation of bone marrow |
| WO2022133282A1 (en) | 2020-12-18 | 2022-06-23 | Ossium Health, Inc. | Methods of cell therapies |
| CN113331176B (zh) * | 2021-06-01 | 2022-04-29 | 零下十八度(北京)生物科技有限公司 | 一种脐带间充质干细胞冻存液 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101718375B1 (ko) | 2007-12-04 | 2017-03-22 | 프로테오바이오엑티브스 피티와이 엘티디 | 전구 세포의 보호 및 그의 분화 조절 |
| GB0822246D0 (en) * | 2008-12-05 | 2009-01-14 | Reneuron Ltd | Composition |
| CN105939601B (zh) * | 2014-01-30 | 2020-03-10 | 豪夫迈·罗氏有限公司 | 在室温稳定全血 |
| KR102582602B1 (ko) * | 2015-05-05 | 2023-09-25 | 메조블라스트 인터내셔널 에스에이알엘 | 효능 검정 |
| US20180325957A1 (en) * | 2015-10-23 | 2018-11-15 | Rigshospitalet | Stem cell therapy based on adipose-derived stem cells |
| CN109843305B (zh) * | 2016-08-14 | 2023-03-10 | 雷蒙特亚特特拉维夫大学有限公司 | 治疗神经障碍的间充质细胞来源的外泌体 |
-
2019
- 2019-09-18 WO PCT/EP2019/074991 patent/WO2020058324A1/en active Search and Examination
- 2019-09-18 CN CN201980060870.9A patent/CN112770628B/zh active Active
- 2019-09-18 US US17/276,340 patent/US11930808B2/en active Active
- 2019-09-18 MX MX2021002932A patent/MX2021002932A/es unknown
- 2019-09-18 AU AU2019341538A patent/AU2019341538B2/en active Active
- 2019-09-18 PT PT197829112T patent/PT3852525T/pt unknown
- 2019-09-18 BR BR112021005257-7A patent/BR112021005257B1/pt active IP Right Grant
- 2019-09-18 JP JP2021510380A patent/JP7401865B2/ja active Active
- 2019-09-18 ES ES19782911T patent/ES2948810T3/es active Active
- 2019-09-18 KR KR1020217010898A patent/KR102506822B1/ko active IP Right Grant
- 2019-09-18 CA CA3112505A patent/CA3112505C/en active Active
- 2019-09-18 EP EP19782911.2A patent/EP3852525B1/en active Active
-
2021
- 2021-02-24 IL IL281105A patent/IL281105B/en unknown
- 2021-03-12 CO CONC2021/0003290A patent/CO2021003290A2/es unknown
- 2021-03-17 CL CL2021000656A patent/CL2021000656A1/es unknown
-
2023
- 2023-02-08 US US18/166,195 patent/US20230247981A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210321606A1 (en) | 2021-10-21 |
| IL281105B (en) | 2022-05-01 |
| CA3112505A1 (en) | 2020-03-26 |
| BR112021005257B1 (pt) | 2023-12-26 |
| JP2022501322A (ja) | 2022-01-06 |
| IL281105A (en) | 2021-04-29 |
| ES2948810T3 (es) | 2023-09-19 |
| KR102506822B1 (ko) | 2023-03-06 |
| AU2019341538B2 (en) | 2023-04-20 |
| WO2020058324A1 (en) | 2020-03-26 |
| BR112021005257A2 (pt) | 2021-06-15 |
| CL2021000656A1 (es) | 2021-09-03 |
| PT3852525T (pt) | 2023-06-02 |
| EP3852525A1 (en) | 2021-07-28 |
| CA3112505C (en) | 2023-06-20 |
| CN112770628B (zh) | 2022-07-01 |
| AU2019341538A1 (en) | 2021-03-18 |
| US20230247981A1 (en) | 2023-08-10 |
| EP3852525B1 (en) | 2023-05-10 |
| MX2021002932A (es) | 2021-06-15 |
| KR20210089140A (ko) | 2021-07-15 |
| US11930808B2 (en) | 2024-03-19 |
| CN112770628A (zh) | 2021-05-07 |
| JP7401865B2 (ja) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021003290A2 (es) | Método para obtener una población enriquecida de células madre mesenquimales funcionales, células obtenidas de la misma y composiciones que las comprenden. | |
| CU20110096A7 (es) | Compuestos que expanden las células madre hematopoyéticas | |
| CL2019002664A1 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados. | |
| BR112016025331A2 (pt) | composições antimicrobianas | |
| AR107967A1 (es) | Ácido hialurónico modificado, método para su preparación y usos del mismo | |
| GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
| CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
| BR112015017174A2 (pt) | preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico | |
| BR112017024013A2 (pt) | composições compreendendo células tronco mesenquimatosas e seus usos | |
| MX2019010385A (es) | Dispositivos, metodos y composiciones utiles en la crio-conservacion, -almacenamiento, -transporte y aplicacion de celulas terapeuticas de mamiferos. | |
| EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| BR112013004616A2 (pt) | diferenciação das células tronco embrionárias humanas | |
| EA201790025A1 (ru) | Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга | |
| WO2013188336A3 (en) | Bioactive bone graft substitutes | |
| BR112015032570A2 (pt) | lipoenchimento com células-tronco derivadas de tecido adiposo expandidas ex vivo para preenchimento de mama estético ou para preenchimento e/ou rejuvenescimento facial | |
| MX2020004811A (es) | Métodos y composiciones de reconstrucción no mieloablativa de médula ósea. | |
| CO2020007275A2 (es) | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas | |
| BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
| BR112017019189A2 (pt) | agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo | |
| NZ723169A (en) | Fgf-18 in graft transplantation and tissue engineering procedures | |
| MX2021003383A (es) | Metodos para diferenciar celulas troncales mesenquimales. | |
| CL2016001130A1 (es) | Composiciones sólidas de triglicéridos y usos de estas | |
| BR112014027333A2 (pt) | composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados | |
| Sergeev et al. | Cell therapy of osteogenesis imperfecta |